Abstract
More than 60 human immunodeficiency virus protease inhibitors were examined for the structure-activity relationship between metabolic stability, CYP3A4 inhibitory potency, and substrate-induced binding spectra with a ferric form of P450 in human liver microsomes. A positive relationship was found between CYP3A4 inhibitory potency and metabolic stability; namely, compounds that were more potent for the CYP3A4 inhibition generally were more metabolically stable. In addition, the compounds formed two clusters defined by the distinct type of substrate-induced P450 binding spectra: the compounds with type II binding spectra were more stable metabolically and more potent for the CYP3A4 inhibition than those with type I binding spectra. The structure-activity relationship suggested that the presence and position of heterocyclic nitrogen on the pyridine moiety play an important role in determining the manner of interaction with P450 and the magnitude of CYP3A4 inhibition/metabolic stability in the series of structurally related human immunodeficiency virus protease inhibitors under development.
Footnotes
-
Send reprint requests to: Masato Chiba, Ph.D., WP75-200, Department of Drug Metabolism, Merck Research Laboratories, West Point, PA 19486. E-mail: chibam{at}banyu.co.jp
- Abbreviations used are::
- HIV
- human immunodeficiency virus
- P450
- human cytochrome P450
- CYP3A4
- human cytochrome P450 3A4
- G6P
- glucose 6-phosphate
- LC-MS
- liquid chromatography-mass spectroscopy
- CLmet
- in vitro metabolic clearance
- HPLC
- high-performance liquid chromatography.
- Received June 6, 2000.
- Accepted September 5, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|